The following sessions will be taking place on Saturday 17 November 2012.
the symposia programme
Please click here to download the full Symposia list as one PDF file
abstract sessions
POSTER DISCUSSION SESSIONS
Click here to download the full poster discussion sessions list as one PDF file.
ORAL ABSTRACT SESSIONS
Click here to download the full oral abstract sessions list as one PDF file.
| Oral Abstract Session | Time | Section |
| Saturday, 17 November 2012 | ||
| 13. TB outbreaks and contact investigations | 12:30-13:30 | Tuberculosis |
| 14. TB hotspots: from the genome to the community | 12:30-13:30 | Tuberculosis |
| 15. TB-HIV: the promise of life but the reality of death | 12:30-13:30 | HIV |
plenary sessions
Speaker: Anneke Hesseling (South Africa) - Director, Paediatric Research, Desmond Tutu TB Centre, University of Stellenbosch, South Africa
Time: 09:00 - 10:00
Room: Plenary Hall
Plenary session 3:
"Childhood TB: we need to do more"
Click here for full details on the Plenary session 3.
meet the expert sessions
The 'Meet the Expert' sessions bring in experts in various fields, to meet with small groups of participants to discuss, face to face, the challenges and opportunities presented by working to promote lung health.
These sessions are free of charge for registered participants only. The number of persons attending each session should not exceed 30.
Registration for the 'Meet the expert' sessions is available on site, at the conference registration desk. Participation will be on a first-come, first-served basis.
01. Impact of treatment on TB transmission, and implications for in- and out-patient therapy
02. Monitoring and Evaluation for Advocacy, Communications and Social Mobilisation
05. Management of Paediatric MDR TB
07. Cost-effective care for asthma in low income settings
01. IMPACT OF TREATMENT ON TB TRANSMISSION, AND IMPLICATION FOR IN-AND OUT-PATIENT THERAPY
08:00 - 08:50: Room: Plenary Theatre
This session will emphasise a new, focused approach to TB transmission control that we are calling F-A-S-T: Finding cases Actively by cough surveillance, Separation and exposure reduction, and prompt, effective Treatment based on rapid molecular DSTs. We will review the evidence supporting an extremely rapid impact of DST-based treatment on transmission, even while sputum smear and culture remain positive. We will discuss the steps needed to implement FAST on the ground and how to monitor its success in reducing exposure time in institutions.
02. monitoring and evaluation for advocacy, communication and social mobilisation
PATIENT THERAPY
08:00 - 08:50: Room: Conference Hall 1
Monitoring starts at the conception of tuberculosis control project by developing a clear, simply SMART objectives. The objectives will at first sight show the indicators to be monitored and evaluated. There are five categories of evaluation that could be used at different times in the life of the project to determine the effectiveness of the project. These categories are; baseline, formative, process, outcome and impact.
03. best rational use of available anti-tuberculosis drugs: building a treatment regimen for drug-resistant tuberculosis
08:00 - 08:50: Room: Conference Hall 2
MDR-TB and XDR-TB are generally thought to have high mortality rates and they are a challenge for the TB control. However, even patients with TB with a very extensive pattern of resistance can be cured using adequately the available antituberculosis drugs. In this Meet the Expert session the role of all the anti-TB drugs in the treatment of the DR-TB will be analyzed, even those with suspect or confirmed "in vitro" resistance. The next important questions regarding the treatment of DR-TB will be addressed in this Meet the Expert session: 1). What is the possible role of the first line anti-TB drugs in the treatment of DR-TB; 2). What is the best fluoroquinolone and its role in the XDR-TB treatment, 3). What is the best logical sequence to introduce the second line drugs (SLD) injectables. 4). What is the most rational introduction of the other SLD (thioamides, cycloserine, aminosalicylic acid). 5. What is the role of the other possible anti-TB drugs like clofazimine, amoxicillin with clavulanate, linezolid, carbapenems, thioacetazone, clarithromycin, bedaquiline, delamanid, and other new drugs in investigation. 6. Pharmacological issues around management of TB and MDR-TB in HIV-infected patients.
04. laboratory accreditation
08:00 - 08:50: Room: Conference Hall 3
This session will present the Global Laboratory Initiative (GLI) Stepwise Process towards Laboratory Accreditation and discuss how this tool developed by the GLI is complementary to the Stepwise laboratory improvement process towards accreditation (SLIPTA) being rolled out in the African region. A variety of training materials on quality management system implementation are available and ready to use which will be highlighted during this session. The session will also discuss the available guidance to meet requirements for TB laboratory network accreditation.
05. management of paediatric mdr tb
08:00 - 08:50: Room: 304/305
This will be an interactive session on the management of MDR- and XDR-TB in children with a brief introductory talk and 1-2 case discussions to get the discussion going. We will address issues such as who should be treated and why (confirmed vs. presumed diagnosis), drug treatment and adverse effects, preventive therapy and HIV co-infection
06. application of Mpower
08:00 - 08:50: Room: 306
The World Health Organization's MPOWER is a policy package of measures intended to assist in the country-level implementation of effective interventions to reduce the demand for tobacco, contained in the WHO FCTC. This interactive session will discuss the practical and operational issues related to the implementation of MPOWER in high tobacco burden settings. The session will include a quick over view of some of the emerging learning for each of these measures from India, as well as consideration of how governments can approach the issue of appropriate levels of investment for comprehensive tobacco control.
07. cost-effective care for asthma in low-income settings
08:00 - 08:50: Room: 401/402
In this session we will consider criteria for selecting disease management interventions for widespread implementation in resource-poor settings. We will then apply these criteria to the case of asthma in order to identify the "best buys" for asthma management. The presentation will focus in particular on inhaled corticosteroids but will also consider other, non-pharmacological aspects of asthma management.
union ADMINISTRATIVE meetings
| Saturday, 17 November 2012 | ||
| 10:15 - 13:15 | The Union Board of Directors | Room: 401/402 |
| 19:00 - 20:00 |
The Union Board of Directors | Room: 401/402 |
| Saturday, 17 November 2012 | ||
| 16:00 - 18:00 | General Assembly of The Union / Closing Ceremony | Room: Plenary hall |
side meetings
Follow the last conference in Lille through photos and videos